Date Title Alternative
2024-03-01 Coverage paused Download | Show Close
2024-01-31 Volume update on UK project Download | Show Close
2023-11-15 Guidance reiterated, but with reduced visibility Show Close
2023-10-04 A new deal Show Close
2023-08-15 Full-year guidance suggests growth has returned Show Close
2023-05-15 Working through 2022 order book Show Close
Research | 15 May 2023 | Irisity

Working through 2022 order book

 

A step in the right direction

Q1 revenues came in at SEK 27.5m, showing growth of -9% y/y and 123% q/q. Sales stemmed partly from the order book of SEK 45m that was presented with the company’s Q4 2022 report. Beyond its order book, the company has won deals that were realised during Q1. EBITDA in the quarter was SEK -5.5m. Profitability has been hindered by the active sales work undertaken at a number of large international trade fairs during the quarter. We thus believe the company’s guidance for improved profitability and growth during the year is fair. After the quarter closed, the company conducted a directed share issue of SEK 17.5m to the newly appointed CEO. This, together with the available cash of SEK 31m, strengthens Irisity’s financial position.

Unchanged view on technology, but questions regarding delivery capacity

We have enormous confidence in Irisity’s technology, thanks to the technical validation it has received from several large players in the field. In Q4, the company signed two framework agreements with key players in the ecosystem. Moreover, interest in the industry for software investments that facilitate surveillance work is substantial. During 2022, Irisity had repeated problems with project delivery. We believe this was partly the result of winning larger and more complex projects for which it lacked the full delivery capacity. We consider the robust q/q growth seen in Q1 to be proof the company is now starting to deliver.

 

Estimates remain cautious

Its Q1 sales suggest Irisity has now increased its delivery capacity and is eliminating some of the red flags we have previously raised about this. We have made only marginal estimate changes to revenues for our forecast period, as the cost base was slightly higher (by SEK 7m) than we had expected for the full year. Thanks to the capital injection received via the directed share issue, we have lowered the required rate of return in our valuation from 35% to 30%, which has led us to lift our fair value to SEK 9.1–9.5.

 

2023-02-28 Order book shows growth returning Show Close
2022-11-15 Most challenges lie ahead Show Close
2022-08-17 Organic growth accelerates Show Close
2022-05-25 Capital Market Day sets the pace going forward Show Close
2022-02-21 MRR growth and gross margin reach record highs Show Close
2021-08-09 Accelerating growth Show Close
2021-05-10 In line with our expectations and confirms commercialization plan Show Close